(Bang et al., 2013) Most recently, immunomodulation including using immune checkpoint inhibitors have shown benefit in various tumor types, such as tumors expressing PDL1, (Sullivan et al., 2013; Muro et al., 2014) particularly with concurrent inflammatory component within the tumor‐bed (Keenan et al., 2013; Le and Jaffee, 2013; June et al., 2014; Maus et al., 2014; Melero et al., 2014; Mellman et al., 2011). This evidence concerns the gene CD274 and neoplasm.